9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Safety Study of MGD009 in B7-H3-expressing Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Safety Study of MGD009 in B7-H3-expressing Tumors

Safety Study of MGD009 in B7-H3-expressing Tumors

Estimated reading time: < 1 min

Condition: Mesothelioma

Estimated Enrollment: 200

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Number of participants with adverse events,  Peak plasma concentration,  Number of participants that develop anti-drug antibodies, Change in tumor volume

Interventions: MGD009,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: December 2019

Completion Date: March 2020

Last  Posted Date: March 6, 2019

Location: UCLA, Los Angeles, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02628535

Was this article helpful?
Dislike 0